We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sartorius Stedim Biotech SA | EU:DIM | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.70 | 0.83% | 207.40 | 207.20 | 207.40 | 207.50 | 205.00 | 205.90 | 5,958 | 10:32:58 |
From May 2022 to May 2024
By Joshua Kirby
Sartorius AG said Friday that it has reached a deal to buy French gene-therapy technology company Polyplus from a group of private investors for around 2.4 billion euros ($2.62 billion)
Strasbourg-based Polyplus should make sales in the double digits of millions of euros in 2023, along with a "substantial" profit margin, Sartorius said.
The company is active in fields including transfection reagents, plasmid design and protein manufacturing, and also has sites in Belgium, the U.S. and China, Sartorius said.
The German pharmaceutical firm will fund the acquisition from investors including Archimed and WP GG Holdings via a bank loan, to be repaid with instruments that could include an equity component, it said.
The transaction should be completed in the third quarter this year, subject to standard approvals and conditions, Sartorius said.
Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby
(END) Dow Jones Newswires
March 31, 2023 03:21 ET (07:21 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sartorius Stedim Biotech Chart |
1 Month Sartorius Stedim Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
